![]() Earnings Synthetic Biologics reported in-line EPS of -0.03 versus an estimate of -0.03. ![]() Here's what investors need to know about the announcement. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. Synthetic Biologics (AMEX:SYN) reported its Q1 earnings results on Monday, at 08:00 AM. Our system considers the available information about the company and then compares it to all the other stocks we have data on to get a percentile-ranked value. It has collaborations with Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center and a clinical trial agreement with Washington University School of Medicine in St. What this means: Synthetic Biologics Inc (SYN) gets an Overall Rank of 53, which is an above average rank under InvestorsObserver's stock ranking system. #Syn stock news pdf#In addition, the company develops clinical stage products, such as SYN-006 to prevent aGVHD and infection by carbapenem resistant enterococci SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics SYN-005 for the prevention and treatment of pertussis and VCN-11 to treat cancer. Volatile ride for Synthetics Biologics Inc stock price on Thursday moving between 1.29 and 1.50 (Updated on Sep 08, 2022) Buy or Hold candidate since Gain 0.72 PDF The Synthetics Biologics Inc stock price fell by -0.71 on the last day (Thursday, 8th Sep 2022) from 1.40 to 1.39. It also develops VCN-01 for the treatment of patients with pancreatic cancer, head and neck squamous cell carcinoma, colorectal cancer, and retinoblastoma. The company's lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. ![]() Synthetic Biologics, Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |